Head-to-head evidence
istradefylline vs VG081821AC
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: adenosine A2A · full Parkinson's Disease pipeline
istradefylline · Nourianz
Marketed by Kyowa Kirin
NCT01968031 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 613 participants and a patient diary-based clinical primary endpoint. Although the Week 12 median OFF time numerically favored both istradefylline doses, the registry provides no p-value or confidence interval, so whether the primary endpoint was statistically met is unclear.
VG081821AC
Developed by Vimgreen Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07725562 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: istradefylline's landscape · VG081821AC's landscape